Overall Fundamental outlook

|fundrankingplaceholder|
|techrankingplaceholder|

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for DIVISLAB
Revenue projections for DIVISLAB

With DIVISLAB's revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.

Financial Ratios:

currentRatio 5.431000
forwardPE 47.388103
debtToEquity 0.042000
earningsGrowth 0.136000
revenueGrowth 0.095000
grossMargins 0.612410
operatingMargins 0.287530
trailingEps 96.620000
forwardEps 142.504120

A current ratio of 5.431 for DIVISLAB implies that the company has ample liquidity to meet its short-term debts. DIVISLAB's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
Positive gross and operating margins for DIVISLAB highlight the company's profitability. These metrics reflect DIVISLAB's efficiency in controlling costs while generating strong revenue from its core operations, signaling robust financial health.
DIVISLAB's forward EPS being higher than its trailing EPS indicates that the company is expected to achieve greater profitability this financial year. This suggests improving earnings and a stronger financial position compared to the previous year's performance.

Price projections:

Price projections for DIVISLAB
Price projections for DIVISLAB

Over time, price projections for DIVISLAB have been gradually revised upward, reflecting increasing optimism about the company's future performance. This trend suggests analysts are growing more confident in DIVISLAB's ability to deliver strong results and achieve higher market value.

Insider Transactions:

Insider Transactions for DIVISLAB
Insider Transactions for DIVISLAB


8 sales transactions of DIVISLAB were conducted, with market price at 6441.162536621094.During the review period, no sell transactions were executed.The higher number of buys versus sells near DIVISLAB's current price suggests optimism among investors. This buying trend could be interpreted as a sign that the market expects favorable outcomes for the stock in the near future.

Recommendation changes over time:

Recommendations trend for DIVISLAB
Recommendations trend for DIVISLAB


Analysts are favoring DIVISLAB with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider DIVISLAB as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.